Bromfenac ophthalmic - InSite Vision

Drug Profile

Bromfenac ophthalmic - InSite Vision

Alternative Names: Bromfenac ophthalmic 0.075%; ISV-101; ISV-303

Latest Information Update: 07 Jan 2017

Price : $50

At a glance

  • Originator InSite Vision; Sun Pharmaceutical Industries
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • Phase I/II Dry eyes
  • Research Retinal oedema

Most Recent Events

  • 28 Nov 2016 Launched for Ocular inflammation in USA (Ophthalmic)
  • 28 Nov 2016 Launched for Ocular pain (Prevention) in USA (Ophthalmic)
  • 10 Aug 2016 Nicox trasfers the rights for Bromofenac opthalmic in Europe, Africa and Middle East to a pan-European ophthalmic specialty pharmaceutical company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top